The effect of Dextromethorphan premedication on cough, pain, anxiety, procedure duration and sedation during fiber optic bronchoscopy.

The effect of Dextromethorphan premedication on cough, pain, anxiety, procedure duration and sedation during fiber optic bronchoscopy: a randomized, double-blind, placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015060520024N2

Enrollment

Registered

2015-07-06

Start date

2015-06-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory disorder, unspecified. Respiratory disease (chronic) NOS

Interventions

Intervention 1: Ninety minutes before FOB, 90 mg (30 cc) of syrup Dextromethorphan, manufactured by kharazmi pharmaceutical co, code:IRC-1228087158,. Intervention 2: Ninety minutes before FOB, 30cc su

Treatment - Drugs

Placebo

Ninety minutes before FOB, 90 mg (30 cc) of syrup Dextromethorphan, manufactured by kharazmi pharmaceutical co, code:IRC-1228087158,

Ninety minutes before FOB, 30cc sucrose syrup

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Any documented indication for diagnostic Fiber Optic Bronchoscopy; 2- Age>18; Exclusion criteria: 1. Allergy to opioid drugs; 2. Taking sedative drugs during last 48 hours; 3. Pregnant woman; 4. Breastfeeding; 5. Patients with central nervous system diseases; 6. Patients with unstable medical condition; 7. Emergent Fiber Optic Bronchoscopy; 8. Impaired level of consciousness; 9. Intubated patients.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cough intensity. Timepoint: during FOB. Method of measurement: Physicians' self assessment score.;Anxiety intensity. Timepoint: during FOB. Method of measurement: Patients' self assessment score.;Lidocaine requirement. Timepoint: during FOB. Method of measurement: Dose of drug recorded by Physician.;Midazolam requirement. Timepoint: during FOB. Method of measurement: Dose of drug recorded by Physician.;Fentanyl requirement. Timepoint: during FOB. Method of measurement: Dose of drug recorded by Physician.;General perception about procedure. Timepoint: during FOB. Method of measurement: Patients' self assessment score.	—

Measure

Time frame

Cough intensity. Timepoint: during FOB. Method of measurement: Physicians' self assessment score.;Anxiety intensity. Timepoint: during FOB. Method of measurement: Patients' self assessment score.;Lidocaine requirement. Timepoint: during FOB. Method of measurement: Dose of drug recorded by Physician.;Midazolam requirement. Timepoint: during FOB. Method of measurement: Dose of drug recorded by Physician.;Fentanyl requirement. Timepoint: during FOB. Method of measurement: Dose of drug recorded by Physician.;General perception about procedure. Timepoint: during FOB. Method of measurement: Patients' self assessment score.

—

Secondary

Measure	Time frame
General perception about procedure. Timepoint: 2 hours after FOB. Method of measurement: patients' self-assessment score.;Duration of FOB. Timepoint: at the end of FOB. Method of measurement: time in minutes.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Soheil Peiman

Department of Internal medicine, Tehran University of Medical Sciences

s-peiman@tums.ac.ir+98 21 6693 9922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026